Kitazato

Kitazato Net Debt / EBITDA

The Net Debt to EBITDA of Kitazato (368A.T) as of Nov 17, 2026 is -1.96. In the previous year, Net Debt to EBITDA was -1.75 — a change of 12.16% (lower).

Net Debt / EBITDA

-1.96

YoY

12.16%

Last updated:

Net Debt to EBITDA of Kitazato is 2025 -1.96 . Net Debt to EBITDA of Kitazato was 2024 -1.75 . It decreases by 12.16% lower compared to the previous year.

The Kitazato Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2023
-1.55 JPY
Jan 1, 2024
-1.75 JPY
Jan 1, 2025
-1.96 JPY
The Kitazato Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
-1.96+12.16%
-1.75+12.58%
-1.55—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Kitazato Stock analysis

What does Kitazato do? Kitazato Corp manufactures and sells medical devices, reagents, and related products for infertility treatment, specializing in reproductive engineering technology for artificial insemination, in vitro fertilization, and cell cryopreservation. The company produces consumables such as medical equipment and reagents used in in vitro fertilization and intracytoplasmic sperm injection, including media, cryo devices, medical devices, and micro tools. Kitazato Corp distributes its products globally, serving markets in Japan, Europe, the United States, China, and India, with a focus on research reagents and medical equipment for infertility treatment. The firm also manufactures and sells medical equipment parts, provides genetic testing services, and offers medical equipment for the elderly. Additionally, Kitazato Corp engages in market research, acquisition of local licenses, and contract management of living cells, expanding its reach into regenerative medicine and related fields. These services and products target healthcare providers, fertility clinics, and research institutions worldwide. Kitazato Corp's revenue streams include the sale of consumables, medical devices, and reagents, as well as genetic testing and contract management services. The company's global distribution network supports sales across key regions, with a strong emphasis on infertility treatment solutions and regenerative medicine technologies. Kitazato is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Kitazato stock

Net Debt to EBITDA of Kitazato is -1.96 in 2025.

Net Debt to EBITDA of Kitazato changed from -1.75 to -1.96, representing a 12.16% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA Kitazato since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's Kitazato with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Kitazato

All Key Metrics — Kitazato